Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Metal-Based Prodrugs and Nanoparticles in Cancer Therapy
share announcement

Metal-Based Prodrugs and Nanoparticles in Cancer Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (10 August 2023) | Viewed by 8238

Special Issue Editors

Dr. Irina Naletova

E-Mail Website
Guest Editor
Institute of Crystallography, National Research Council (CNR), Via Paolo Gaifami, 18, 95126 Catania, Italy
Interests: metal homeostasis; ionophores; nanomedicine; theranostics; anticancer drugs
Prof. Dr. Barbara Tomasello

E-Mail Website1 Website2
Guest Editor
1. Department of Drug and Health Sciences, Section of Biochemistry, University of Catania, 95125 Catania, Italy
2. Research Center on Nutraceuticals and Health Products (CERNUT), University of Catania, 95125 Catania, Italy
3. Molecular, Preclinical and Translational Imaging Research Centre (IMPRONTE), University of Catania, 95125 Catania, Italy
Interests: nutraceuticals; cancer biology; biomarkers; oxidative stress and natural compounds in cancer, aging, degenerative and metabolic disease; cancer epigenetics; DNA damage and comet assay; inflammation; nanosystem for drug delivery
Special Issues, Collections and Topics in MDPI journals
Dr. Victor V. Pleshkan

E-Mail Website
Guest Editor
1. Gene Immunooncotherapy Group, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 117997 Moscow, Russia
2.Gene Oncotherapy Sector, Institute of Molecular Genetics of National Research Centre "Kurchatov Institute", 123182 Moscow, Russia
Interests: cancer; gene therapy; immunotherapy; non-viral delivery; translational research; tumor microenvironment

Special Issue Information

Dear Colleagues,

In recent decades, the use of prodrugs and nanoparticles as drug delivery systems offers the possibility of developing sophisticated targeting therapeutics as powerful nanomedicine tools, enabling for biomedical applications in prevention, diagnosis, treatment of cancer disease, radiomics and theranostics. Transition metal complexes have been used in medicine to treat cancer for more than 40 years but many concerns are responsible for the current stall in the field of metal anticancer drugs. Nowadays, one of the strategies is to convert them into inert prodrugs, so that they can travel to the tumour site unchanged and release the drug in its active form only there. Moreover, the development of novel nanodrug delivery systems have been attracting growing interests as allow to improve pharmacokinetic and pharmacodynamic properties and show more therapeutic efficacy and less potential toxicity. In addition to nanostructures for delivering of known chemotherapeutic agents, the inclusion/combination of metal complex in/and nano-system may also be a reliable approach and the future for cancer therapy.

The present Special Issue of Pharmaceutics welcomes contributions dealing with all aspects of metallo-prodrugs and nanotechnology in drug delivery research, including

  • synthetic methods for the realization of novel metallo-prodrugs, nanosystems and/or metallodrug in nanoparticles
  • analysis of pharmacokinetic and pharmacodynamic properties of metal-based prodrugs, chemotherapeutics or metal drugs encapsulated in nanostructures
  • in vitro or in vivo evaluation of therapeutic properties of metal-based prodrugs, nanoparticles and nanostructured materials functionalized with therapeutic metal complexes.
  • Use of metal-pro drugs or/and nanoparticles in diagnosis, medical imaging, therapy and theranostics as well

We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Barbara Tomasello
Dr. Irina Naletova
Dr. Victor V. Pleshkan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapy
  • metalprodrugs
  • nanomedicine
  • imaging
  • clinical trials
  • metal-based drugs
  • metal complexes

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 6768 KiB  
Article
Influence of Silver Nanoparticles on the Growth of Ascitic and Solid Ehrlich Adenocarcinoma: Focus on Copper Metabolism
by Daria N. Magazenkova, Ekaterina A. Skomorokhova, Mohammad Al Farroukh, Maria S. Zharkova, Zena M. Jassem, Valeria E. Rekina, Olga V. Shamova, Ludmila V. Puchkova and Ekaterina Y. Ilyechova
Pharmaceutics 2023, 15(4), 1099; https://doi.org/10.3390/pharmaceutics15041099 - 29 Mar 2023
Viewed by 1491
Abstract
The link between copper metabolism and tumor progression motivated us to use copper chelators for suppression of tumor growth. We assume that silver nanoparticles (AgNPs) can be used for lowering bioavailable copper. Our assumption is based on the ability of Ag(I) ions released [...] Read more.
The link between copper metabolism and tumor progression motivated us to use copper chelators for suppression of tumor growth. We assume that silver nanoparticles (AgNPs) can be used for lowering bioavailable copper. Our assumption is based on the ability of Ag(I) ions released by AgNPs in biological media and interfere with Cu(I) transport. Intervention of Ag(I) into copper metabolism leads to the replacement of copper by silver in ceruloplasmin and the decrease in bioavailable copper in the bloodstream. To check this assumption, mice with ascitic or solid Ehrlich adenocarcinoma (EAC) were treated with AgNPs using different protocols. Copper status indexes (copper concentration, ceruloplasmin protein level, and oxidase activity) were monitored to assess copper metabolism. The expression of copper-related genes was determined by real-time PCR in the liver and tumors, and copper and silver levels were measured by FAAS. Intraperitoneal AgNPs treatment beginning on the day of tumor inoculation enhanced mice survival, reduced the proliferation of ascitic EAC cells, and suppressed the activity of HIF1α, TNF-α and VEGFa genes. Topical treatment by the AgNPs, which was started together with the implantation of EAC cells in the thigh, also enhanced mice survival, decreased tumor growth, and repressed genes responsible for neovascularization. The advantages of silver-induced copper deficiency over copper chelators are discussed. Full article
(This article belongs to the Special Issue Metal-Based Prodrugs and Nanoparticles in Cancer Therapy)
►▼ Show Figures

Graphical abstract

19 pages, 7223 KiB  
Article
Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy
by Renata Carolina Alves, Richard Perosa Fernandes, Renan Lira de Farias, Patricia Bento da Silva, Raquel Santos Faria, Christian Rafael Quijia, Regina Célia Galvão Frem, Ricardo Bentes Azevedo and Marlus Chorilli
Pharmaceutics 2022, 14(11), 2458; https://doi.org/10.3390/pharmaceutics14112458 - 15 Nov 2022
Cited by 5 | Viewed by 1684
Abstract
Breast cancer is the most frequent cause of cancer death in women, representing the fifth leading cause of cancer death overall. Therefore, the growing search for the development of new treatments for breast cancer has been developed lately as well as drug delivery [...] Read more.
Breast cancer is the most frequent cause of cancer death in women, representing the fifth leading cause of cancer death overall. Therefore, the growing search for the development of new treatments for breast cancer has been developed lately as well as drug delivery systems such as biocompatible metal–organic Frameworks (bio-MOFs). These may be promising and attractive for drug incorporation and release. The present study aims to develop a drug carrier system RCA (bioMOF-100 submitted to the activation process) containing incorporated curcumin (CCM), whose material surface is coated with folic acid molecules (FA) to promote the targeting of drug carrier systems to the tumor region. They were synthesized and characterized using several characterization techniques. The materials were submitted to drug encapsulation tests, whose encapsulation efficiency was 32.80% for CCM@RCA-1D. Using the 1H nuclear magnetic resonance (NMR) spectroscopy technique, it was possible to verify the appearance of signals referring to folic acid, suggesting success in the functionalization of these matrices. In vitro tests such as cell viability and type of cell death were evaluated in both series of compounds (CCM@RCA-1D, CCM@RCA-1D/FA) in breast tumor lines. The results revealed low toxicity of the materials and cell death by late apoptosis. Thus, these results indicate that the matrices studied can be promising carriers in the treatment of breast cancer. Full article
(This article belongs to the Special Issue Metal-Based Prodrugs and Nanoparticles in Cancer Therapy)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

32 pages, 2364 KiB  
Review
Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy
by Irina Naletova, Barbara Tomasello, Francesco Attanasio and Victor V. Pleshkan
Pharmaceutics 2023, 15(5), 1346; https://doi.org/10.3390/pharmaceutics15051346 - 27 Apr 2023
Cited by 2 | Viewed by 1612
Abstract
Immunotherapy is among the most effective approaches for treating cancer. One of the key aspects for successful immunotherapy is to achieve a strong and stable antitumor immune response. Modern immune checkpoint therapy demonstrates that cancer can be defeated. However, it also points out [...] Read more.
Immunotherapy is among the most effective approaches for treating cancer. One of the key aspects for successful immunotherapy is to achieve a strong and stable antitumor immune response. Modern immune checkpoint therapy demonstrates that cancer can be defeated. However, it also points out the weaknesses of immunotherapy, as not all tumors respond to therapy and the co-administration of different immunomodulators may be severely limited due to their systemic toxicity. Nevertheless, there is an established way through which to increase the immunogenicity of immunotherapy—by the use of adjuvants. These enhance the immune response without inducing such severe adverse effects. One of the most well-known and studied adjuvant strategies to improve immunotherapy efficacy is the use of metal-based compounds, in more modern implementation—metal-based nanoparticles (MNPs), which are exogenous agents that act as danger signals. Adding innate immune activation to the main action of an immunomodulator makes it capable of eliciting a robust anti-cancer immune response. The use of an adjuvant has the peculiarity of a local administration of the drug, which positively affects its safety. In this review, we will consider the use of MNPs as low-toxicity adjuvants for cancer immunotherapy, which could provide an abscopal effect when administered locally. Full article
(This article belongs to the Special Issue Metal-Based Prodrugs and Nanoparticles in Cancer Therapy)
►▼ Show Figures

Figure 1

21 pages, 2483 KiB  
Review
Recent Developments in Heteroatom/Metal-Doped Carbon Dot-Based Image-Guided Photodynamic Therapy for Cancer
by Rajkumar Sekar, Nagaraj Basavegowda, Saktishree Jena, Santhoshkumar Jayakodi, Pandian Elumalai, Amballa Chaitanyakumar, Prathap Somu and Kwang-Hyun Baek
Pharmaceutics 2022, 14(9), 1869; https://doi.org/10.3390/pharmaceutics14091869 - 05 Sep 2022
Cited by 16 | Viewed by 2688
Abstract
Carbon nanodots (CNDs) are advanced nanomaterials with a size of 2–10 nm and are considered zero-dimensional carbonaceous materials. CNDs have received great attention in the area of cancer theranostics. The majority of review articles have shown the improvement of CNDs for use in [...] Read more.
Carbon nanodots (CNDs) are advanced nanomaterials with a size of 2–10 nm and are considered zero-dimensional carbonaceous materials. CNDs have received great attention in the area of cancer theranostics. The majority of review articles have shown the improvement of CNDs for use in cancer therapy and bioimaging applications. However, there is a minimal number of consolidated studies on the currently developed doped CNDs that are used in various ways in cancer therapies. Hence, in this review, we discuss the current developments in different types of heteroatom elements/metal ion-doped CNDs along with their preparations, physicochemical and biological properties, multimodal-imaging, and emerging applications in image-guided photodynamic therapies for cancer. Full article
(This article belongs to the Special Issue Metal-Based Prodrugs and Nanoparticles in Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop